诺西那生 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "诺西那生" in Chinese language version.

refsWebsite

Global rank Chinese rank

37web.archive.org

1^st place

13doi.org

2^nd place

23^rd place

9nih.gov

4^th place

5^th place

3worldcat.org

5^th place

12^th place

3smanewstoday.com

low place

2europa.eu

68^th place

209^th place

1canada.ca

1,712^th place

3,316^th place

1medsafe.govt.nz

low place

6,677^th place

1medicines.org.uk

3,823^rd place

3,456^th place

1who.int

195^th place

179^th place

1fda.gov

447^th place

581^st place

1thelancet.com

2,393^rd place

1,199^th place

1sps.nhs.uk

low place

1nytimes.com

7^th place

31^st place

1dr.dk

1,346^th place

7,509^th place

1abcnyheter.no

low place

1reuters.com

49^th place

81^st place

1springer.com

274^th place

320^th place

1rupress.org

low place

1curesma.org

low place

1cshl.edu

low place

1sciencemag.org

857^th place

506^th place

1the-scientist.com

7,827^th place

5,345^th place

1ionispharma.com

low place

1genengnews.com

low place

1wsj.com

79^th place

143^rd place

1thepharmaletter.com

low place

1brasil.gov.br

9,094^th place

low place

1sma-schweiz.ch

low place

1scoop.co.nz

3,973^rd place

5,713^th place

1zjol.com.cn

6,862^nd place

272^nd place

1228.83

low place

1treatsma.uk

low place

1ntdtv.com

low place

594^th place

1hk01.com

379^th place

11^th place

1udn.com

392^nd place

10^th place

228.83

124.133.228.83

“70万元一针”天价药进医保浙江SAM患者接受首批治疗. ^{[失效連結]}

abcnyheter.no

– Dette er uforståelig og utrolig urettferdig. www.abcnyheter.no. [2018-12-31]. （原始内容存档于2020-12-02）.

brasil.gov.br

Remédio inédito para atrofia muscular espinhal é liberado. 2017-08-25 [2018-12-31]. （原始内容存档于2018-12-13）（巴西葡萄牙语）.

canada.ca

Canada, Health; Canada, Health. Notice: Prescription Drug List (PDL): Multiple additions [2017-08-04]. The Prescription Drug List. Government of Canada. 2017-08-04 [2019-01-01]. （原始内容存档于2020-10-24）.

cshl.edu

Mahy, Brian W.J. FDA approval of life-saving SMA drug is hailed by its researcher-inventor at CSHL. Cold Spring Harbor Laboratory. 2016-12-24 [2019-01-01]. （原始内容存档于2020-11-23）.

curesma.org

Therapeutic Approaches. www.curesma.org. Cure SMA. [2017-01-01]. （原始内容存档于2017-01-01）.

doi.org

Ottesen, Eric W. ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy. Translational Neuroscience. 2017-01-01, 8 (1): 1–6 [2018-12-31]. ISSN 2081-6936. PMC 5382937 . PMID 28400976. doi:10.1515/tnsci-2017-0001. （原始内容存档于2019-10-18）（英语）.
Lunn, Mitchell R; Wang, Ching H. Spinal muscular atrophy. The Lancet. 2008-06, 371 (9630): 2120–2133 [2019-01-03]. doi:10.1016/S0140-6736(08)60921-6.
Zanetta, C; Nizzardo, M; Simone, C; Monguzzi, E; Bresolin, N; Comi, GP; Corti, S. Molecular Therapeutic Strategies for Spinal Muscular Atrophies: Current and Future Clinical Trials. Clinical Therapeutics. 2014-01-01, 36 (1): 128–40. PMID 24360800. doi:10.1016/j.clinthera.2013.11.006.
Finkel, Richard S; Chiriboga, Claudia A; Vajsar, Jiri; Day, John W; Montes, Jacqueline; De Vivo, Darryl C; Yamashita, Mason; Rigo, Frank; Hung, Gene; Schneider, Eugene; Norris, Daniel A; Xia, Shuting; Bennett, C Frank; Bishop, Kathie M. Treatment of infantile-onset spinal muscular atrophy with nusinersen: A phase 2, open-label, dose-escalation study. The Lancet. 2016, 388 (10063): 3017. doi:10.1016/S0140-6736(16)31408-8.
Finkel, Richard S.; Mercuri, Eugenio; Darras, Basil T.; Connolly, Anne M.; Kuntz, Nancy L.; Kirschner, Janbernd; Chiriboga, Claudia A.; Saito, Kayoko; Servais, Laurent; Tizzano, Eduardo; Topaloglu, Haluk; Tulinius, Már; Montes, Jacqueline; Glanzman, Allan M.; Bishop, Kathie; Zhong, Z. John; Gheuens, Sarah; Bennett, C. Frank; Schneider, Eugene; Farwell, Wildon; De Vivo, Darryl C. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. New England Journal of Medicine. 2017-11-02, 377 (18): 1723–1732. doi:10.1056/NEJMoa1702752.
Mercuri, Eugenio; Darras, Basil T.; Chiriboga, Claudia A.; Day, John W.; Campbell, Craig; Connolly, Anne M.; Iannaccone, Susan T.; Kirschner, Janbernd; Kuntz, Nancy L.; Saito, Kayoko; Shieh, Perry B.; Tulinius, Már; Mazzone, Elena S.; Montes, Jacqueline; Bishop, Kathie M.; Yang, Qingqing; Foster, Richard; Gheuens, Sarah; Bennett, C. Frank; Farwell, Wildon; Schneider, Eugene; De Vivo, Darryl C.; Finkel, Richard S. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. New England Journal of Medicine. 2018-02-15, 378 (7): 625–635. doi:10.1056/NEJMoa1710504.
New warning of nusinersen-related communicating hydrocephalus. Reactions Weekly. 2018-08-01, 1714 (1): 3–3 [2018-12-31]. ISSN 1179-2051. doi:10.1007/s40278-018-50183-2. （原始内容存档于2019-04-03）（英语）.
Burghes, Arthur H. M.; Beattie, Christine E. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?. Nature Reviews Neuroscience. 2009-07-08, 10 (8): 597–609 [2019-01-01]. doi:10.1038/nrn2670. （原始内容存档于2021-08-29）.
Edfors, F; Danielsson, F; Hallström, BM; Käll, L; Lundberg, E; Pontén, F; Forsström, B; Uhlén, M. Gene-specific correlation of RNA and protein levels in human cells and tissues.. Molecular systems biology. 2016-10-20, 12 (10): 883 [2019-01-03]. PMID 27951527. doi:10.15252/msb.20167144. （原始内容存档于2021-05-02）.
Rigo, Frank; Hua, Yimin; Krainer, Adrian R.; Bennett, C. Frank. Antisense-based therapy for the treatment of spinal muscular atrophy. The Journal of Cell Biology. 2012-10-01, 199 (1): 21–25 [2019-01-03]. doi:10.1083/jcb.201207087. （原始内容存档于2019-11-29）.
Sampaio-Silva, F; Magalhães, T; Carvalho, F; Dinis-Oliveira, RJ; Silvestre, R. Profiling of RNA degradation for estimation of post mortem interval.. PloS one. 2013, 8 (2): e56507. PMID 23437149. doi:10.1371/journal.pone.0056507.
Singh, NN; Howell, MD; Androphy, EJ; Singh, RN. How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy.. Gene therapy. 2017-09, 24 (9): 520–526 [2019-01-03]. PMID 28485722. doi:10.1038/gt.2017.34. （原始内容存档于2021-05-26）.
Garber, K. Big win possible for Ionis/Biogen antisense drug in muscular atrophy.. Nature Biotechnology. 2016-10-11, 34 (10): 1002–1003. PMID 27727217. doi:10.1038/nbt1016-1002.

dr.dk

Medicinrådet siger nej til lægemiddel til børn med muskelsvind: 'Urimeligt' dyrt （页面存档备份，存于互联网档案馆） Retrieved October 13 2017.

europa.eu

ema.europa.eu

Spinraza. www.ema.europa.eu. European Medicines Agency. [2019-01-01]. （原始内容存档于2021-01-04）.
Spinraza (nusinersen). 歐洲藥品管理局. [2017-10-27]. （原始内容存档于2017-10-28）.

fda.gov

accessdata.fda.gov

Nusinersen US Label (PDF). FDA. December 2016 [2018-12-31]. （原始内容存档 (PDF)于2020-11-23）. For updates see FDA index page for NDA 209531 （页面存档备份，存于互联网档案馆）

genengnews.com

Biogen Shells Out $75M to Develop Ionis' Nusinersen after Positive Phase III Results, Genetic Engineering News, 2016-08-01 [2018-12-31], （原始内容存档于2018-06-14）

hk01.com

姜庚宇. 1劑特效藥內地賣70萬澳洲只需41澳元？藥企：因澳洲該藥納入醫保. 香港01. 2020-08-06 [2020-08-06]. （原始内容存档于2021-07-16）（中文）.

ionispharma.com

ir.ionispharma.com

Biogen and Ionis Pharmaceuticals Announce SPINRAZA (nusinersen) Meets Primary Endpoint at Interim Analysis of Phase 3 CHERISH Study in Later-Onset Spinal Muscular Atrophy. Ionis Pharmaceuticals, Inc. Ionis Pharmaceuticals. [2019-01-01]. （原始内容存档于2017-11-11）（英语）.

medicines.org.uk

Spinraza 12 mg solution for injection - Summary of Product Characteristics (SmPC) - (eMC). eMC. Datapharm. [2019-01-01]. （原始内容存档于2019-02-17）.

medsafe.govt.nz

NEW ZEALAND DATA SHEET: SPINRAZA (PDF). Data Sheets and Consumer Medicine Information. New Zealand Medicines and Medical Devices Safety Authority. [2019-01-01]. （原始内容存档 (PDF)于2021-02-02）.

nih.gov

ncbi.nlm.nih.gov

Ottesen, Eric W. ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy. Translational Neuroscience. 2017-01-01, 8 (1): 1–6 [2018-12-31]. ISSN 2081-6936. PMC 5382937 . PMID 28400976. doi:10.1515/tnsci-2017-0001. （原始内容存档于2019-10-18）（英语）.
Zanetta, C; Nizzardo, M; Simone, C; Monguzzi, E; Bresolin, N; Comi, GP; Corti, S. Molecular Therapeutic Strategies for Spinal Muscular Atrophies: Current and Future Clinical Trials. Clinical Therapeutics. 2014-01-01, 36 (1): 128–40. PMID 24360800. doi:10.1016/j.clinthera.2013.11.006.
Burghes, Arthur H. M.; Beattie, Christine E. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?. Nature Reviews Neuroscience. 2009-07-08, 10 (8): 597–609 [2019-01-01]. doi:10.1038/nrn2670. （原始内容存档于2021-08-29）.
Edfors, F; Danielsson, F; Hallström, BM; Käll, L; Lundberg, E; Pontén, F; Forsström, B; Uhlén, M. Gene-specific correlation of RNA and protein levels in human cells and tissues.. Molecular systems biology. 2016-10-20, 12 (10): 883 [2019-01-03]. PMID 27951527. doi:10.15252/msb.20167144. （原始内容存档于2021-05-02）.
Sampaio-Silva, F; Magalhães, T; Carvalho, F; Dinis-Oliveira, RJ; Silvestre, R. Profiling of RNA degradation for estimation of post mortem interval.. PloS one. 2013, 8 (2): e56507. PMID 23437149. doi:10.1371/journal.pone.0056507.
Geary, RS; Watanabe, TA; Truong, L; Freier, S; Lesnik, EA; Sioufi, NB; Sasmor, H; Manoharan, M; Levin, AA. Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats.. The Journal of pharmacology and experimental therapeutics. 2001-03, 296 (3): 890–7. PMID 11181921.
Dias, N; Stein, CA. Antisense oligonucleotides: basic concepts and mechanisms.. Molecular cancer therapeutics. 2002-03, 1 (5): 347–55. PMID 12489851.
Singh, NN; Howell, MD; Androphy, EJ; Singh, RN. How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy.. Gene therapy. 2017-09, 24 (9): 520–526 [2019-01-03]. PMID 28485722. doi:10.1038/gt.2017.34. （原始内容存档于2021-05-26）.
Garber, K. Big win possible for Ionis/Biogen antisense drug in muscular atrophy.. Nature Biotechnology. 2016-10-11, 34 (10): 1002–1003. PMID 27727217. doi:10.1038/nbt1016-1002.

ntdtv.com

竺穎; 雲濤. 湖南嬰兒救命藥標價70萬刷屏網友：澳洲只需41元. 新唐人電視台 (新唐人). 2020-08-03 [2020-08-06]. （原始内容存档于2020-08-04）（中文）.

nytimes.com

Katie Thomas. Costly Drug for Fatal Muscular Disease Wins F.D.A. Approval. New York Times. 2016-12-30 [2018-12-31]. （原始内容存档于2020-11-08）.

reuters.com

Ben Hirschler. Biogen's pricey muscle drug Spinraza too costly for Britain. Reuters. Reuters. 2018-08-13 [2019-01-01]. （原始内容存档于2020-11-09）（英语）.

rupress.org

jcb.rupress.org

Rigo, Frank; Hua, Yimin; Krainer, Adrian R.; Bennett, C. Frank. Antisense-based therapy for the treatment of spinal muscular atrophy. The Journal of Cell Biology. 2012-10-01, 199 (1): 21–25 [2019-01-03]. doi:10.1083/jcb.201207087. （原始内容存档于2019-11-29）.

sciencemag.org

Wadman, Meredith. Updated: FDA approves drug that rescues babies with fatal neurodegenerative disease. Science. 2016-12-23 [2018-12-31]. （原始内容存档于2017-05-25）.

scoop.co.nz

Treatment for Spinal Muscular Atrophy Now Registered. www.scoop.co.nz. Scoop Health. [2019-01-01]. （原始内容存档于2019-07-06）.

sma-schweiz.ch

Spinraza – Zulassung nun auch in der Schweiz. SMA Schweiz. 2017-09-30 [2018-12-31]. （原始内容存档于2020-10-27）（瑞士高地德语）.

smanewstoday.com

Regulatory Applications for SMA Therapy Nusinersen Accepted in US, EU. BioNews Services, LLC. [2016-11-15]. （原始内容存档于2020-08-15）.
Spinraza Approved by Health Canada for Treating 5q SMA Patients. SMA News Today. 2017-07-06 [2019-01-01]. （原始内容存档于2019-02-17）.
Spinraza Approved in Korea for SMA Treatment, Biogen Announces. SMA News Today. 2018-01-10 [2019-01-01]. （原始内容存档于2019-02-17）.

springer.com

link.springer.com

New warning of nusinersen-related communicating hydrocephalus. Reactions Weekly. 2018-08-01, 1714 (1): 3–3 [2018-12-31]. ISSN 1179-2051. doi:10.1007/s40278-018-50183-2. （原始内容存档于2019-04-03）（英语）.

sps.nhs.uk

Nusinersen. UK Specialist Pharmacy Service. [2016-12-31]. （原始内容存档于2019-04-13）.

the-scientist.com

Offord, Catherine. Oligonucleotide Therapeutics Near Approval. The Scientist. 2016-12-01 [2021-02-08]. （原始内容存档于2018-04-11）.

thelancet.com

Lunn, Mitchell R; Wang, Ching H. Spinal muscular atrophy. The Lancet. 2008-06, 371 (9630): 2120–2133 [2019-01-03]. doi:10.1016/S0140-6736(08)60921-6.

thepharmaletter.com

Biogen to launch Spinraza in Japan soon. 2017-07-10 [2018-12-31]. （原始内容存档于2020-01-12）.

treatsma.uk

NICE refuses to recommend Spinraza to treat SMA. TreatSMA. 2018-08-14 [2019-01-01]. （原始内容存档于2020-12-04）.

udn.com

陳言喬. 5900萬元一針陸藥監局批准「史上最貴藥」臨床試驗. 聯合報. 2022-01-20 [2022-01-20]. （原始内容存档于2022-02-15）.

web.archive.org

Canada, Health; Canada, Health. Notice: Prescription Drug List (PDL): Multiple additions [2017-08-04]. The Prescription Drug List. Government of Canada. 2017-08-04 [2019-01-01]. （原始内容存档于2020-10-24）.
NEW ZEALAND DATA SHEET: SPINRAZA (PDF). Data Sheets and Consumer Medicine Information. New Zealand Medicines and Medical Devices Safety Authority. [2019-01-01]. （原始内容存档 (PDF)于2021-02-02）.
Spinraza 12 mg solution for injection - Summary of Product Characteristics (SmPC) - (eMC). eMC. Datapharm. [2019-01-01]. （原始内容存档于2019-02-17）.
Spinraza. www.ema.europa.eu. European Medicines Agency. [2019-01-01]. （原始内容存档于2021-01-04）.
International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 74 (PDF). World Health Organization: 413–14. [2017-03-13]. （原始内容存档 (PDF)于2020-08-13）.
Nusinersen US Label (PDF). FDA. December 2016 [2018-12-31]. （原始内容存档 (PDF)于2020-11-23）. For updates see FDA index page for NDA 209531 （页面存档备份，存于互联网档案馆）
Ottesen, Eric W. ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy. Translational Neuroscience. 2017-01-01, 8 (1): 1–6 [2018-12-31]. ISSN 2081-6936. PMC 5382937 . PMID 28400976. doi:10.1515/tnsci-2017-0001. （原始内容存档于2019-10-18）（英语）.
Nusinersen. UK Specialist Pharmacy Service. [2016-12-31]. （原始内容存档于2019-04-13）.
Katie Thomas. Costly Drug for Fatal Muscular Disease Wins F.D.A. Approval. New York Times. 2016-12-30 [2018-12-31]. （原始内容存档于2020-11-08）.
Medicinrådet siger nej til lægemiddel til børn med muskelsvind: 'Urimeligt' dyrt （页面存档备份，存于互联网档案馆） Retrieved October 13 2017.
– Dette er uforståelig og utrolig urettferdig. www.abcnyheter.no. [2018-12-31]. （原始内容存档于2020-12-02）.
Ben Hirschler. Biogen's pricey muscle drug Spinraza too costly for Britain. Reuters. Reuters. 2018-08-13 [2019-01-01]. （原始内容存档于2020-11-09）（英语）.
New warning of nusinersen-related communicating hydrocephalus. Reactions Weekly. 2018-08-01, 1714 (1): 3–3 [2018-12-31]. ISSN 1179-2051. doi:10.1007/s40278-018-50183-2. （原始内容存档于2019-04-03）（英语）.
Burghes, Arthur H. M.; Beattie, Christine E. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?. Nature Reviews Neuroscience. 2009-07-08, 10 (8): 597–609 [2019-01-01]. doi:10.1038/nrn2670. （原始内容存档于2021-08-29）.
Edfors, F; Danielsson, F; Hallström, BM; Käll, L; Lundberg, E; Pontén, F; Forsström, B; Uhlén, M. Gene-specific correlation of RNA and protein levels in human cells and tissues.. Molecular systems biology. 2016-10-20, 12 (10): 883 [2019-01-03]. PMID 27951527. doi:10.15252/msb.20167144. （原始内容存档于2021-05-02）.
Rigo, Frank; Hua, Yimin; Krainer, Adrian R.; Bennett, C. Frank. Antisense-based therapy for the treatment of spinal muscular atrophy. The Journal of Cell Biology. 2012-10-01, 199 (1): 21–25 [2019-01-03]. doi:10.1083/jcb.201207087. （原始内容存档于2019-11-29）.
Singh, NN; Howell, MD; Androphy, EJ; Singh, RN. How the discovery of ISS-N1 led to the first medical therapy for spinal muscular atrophy.. Gene therapy. 2017-09, 24 (9): 520–526 [2019-01-03]. PMID 28485722. doi:10.1038/gt.2017.34. （原始内容存档于2021-05-26）.
Therapeutic Approaches. www.curesma.org. Cure SMA. [2017-01-01]. （原始内容存档于2017-01-01）.
Mahy, Brian W.J. FDA approval of life-saving SMA drug is hailed by its researcher-inventor at CSHL. Cold Spring Harbor Laboratory. 2016-12-24 [2019-01-01]. （原始内容存档于2020-11-23）.
Wadman, Meredith. Updated: FDA approves drug that rescues babies with fatal neurodegenerative disease. Science. 2016-12-23 [2018-12-31]. （原始内容存档于2017-05-25）.
Offord, Catherine. Oligonucleotide Therapeutics Near Approval. The Scientist. 2016-12-01 [2021-02-08]. （原始内容存档于2018-04-11）.
Biogen and Ionis Pharmaceuticals Announce SPINRAZA (nusinersen) Meets Primary Endpoint at Interim Analysis of Phase 3 CHERISH Study in Later-Onset Spinal Muscular Atrophy. Ionis Pharmaceuticals, Inc. Ionis Pharmaceuticals. [2019-01-01]. （原始内容存档于2017-11-11）（英语）.
Biogen Shells Out $75M to Develop Ionis' Nusinersen after Positive Phase III Results, Genetic Engineering News, 2016-08-01 [2018-12-31], （原始内容存档于2018-06-14）
Regulatory Applications for SMA Therapy Nusinersen Accepted in US, EU. BioNews Services, LLC. [2016-11-15]. （原始内容存档于2020-08-15）.
Grant, Charley. Surprise Drug Approval Is Holiday Gift for Biogen. Wall Street Journal. 2016-12-27 [2016-12-27]. ISSN 0099-9660. （原始内容存档于2020-11-08）. 参数|newspaper=与模板{{cite web}}不匹配（建议改用{{cite news}}或|website=） (帮助)
Spinraza (nusinersen). 歐洲藥品管理局. [2017-10-27]. （原始内容存档于2017-10-28）.
Spinraza Approved by Health Canada for Treating 5q SMA Patients. SMA News Today. 2017-07-06 [2019-01-01]. （原始内容存档于2019-02-17）.
Biogen to launch Spinraza in Japan soon. 2017-07-10 [2018-12-31]. （原始内容存档于2020-01-12）.
Remédio inédito para atrofia muscular espinhal é liberado. 2017-08-25 [2018-12-31]. （原始内容存档于2018-12-13）（巴西葡萄牙语）.
Spinraza – Zulassung nun auch in der Schweiz. SMA Schweiz. 2017-09-30 [2018-12-31]. （原始内容存档于2020-10-27）（瑞士高地德语）.
Spinraza Approved in Korea for SMA Treatment, Biogen Announces. SMA News Today. 2018-01-10 [2019-01-01]. （原始内容存档于2019-02-17）.
Treatment for Spinal Muscular Atrophy Now Registered. www.scoop.co.nz. Scoop Health. [2019-01-01]. （原始内容存档于2019-07-06）.
https://zj.zjol.com.cn/news.html?id=1500220 （页面存档备份，存于互联网档案馆）引发争议的70万元“天价药”，怎样定价才算合理？
NICE refuses to recommend Spinraza to treat SMA. TreatSMA. 2018-08-14 [2019-01-01]. （原始内容存档于2020-12-04）.
竺穎; 雲濤. 湖南嬰兒救命藥標價70萬刷屏網友：澳洲只需41元. 新唐人電視台 (新唐人). 2020-08-03 [2020-08-06]. （原始内容存档于2020-08-04）（中文）.
姜庚宇. 1劑特效藥內地賣70萬澳洲只需41澳元？藥企：因澳洲該藥納入醫保. 香港01. 2020-08-06 [2020-08-06]. （原始内容存档于2021-07-16）（中文）.
陳言喬. 5900萬元一針陸藥監局批准「史上最貴藥」臨床試驗. 聯合報. 2022-01-20 [2022-01-20]. （原始内容存档于2022-02-15）.

who.int

International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary Names: List 74 (PDF). World Health Organization: 413–14. [2017-03-13]. （原始内容存档 (PDF)于2020-08-13）.

worldcat.org

Ottesen, Eric W. ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy. Translational Neuroscience. 2017-01-01, 8 (1): 1–6 [2018-12-31]. ISSN 2081-6936. PMC 5382937 . PMID 28400976. doi:10.1515/tnsci-2017-0001. （原始内容存档于2019-10-18）（英语）.
New warning of nusinersen-related communicating hydrocephalus. Reactions Weekly. 2018-08-01, 1714 (1): 3–3 [2018-12-31]. ISSN 1179-2051. doi:10.1007/s40278-018-50183-2. （原始内容存档于2019-04-03）（英语）.
Grant, Charley. Surprise Drug Approval Is Holiday Gift for Biogen. Wall Street Journal. 2016-12-27 [2016-12-27]. ISSN 0099-9660. （原始内容存档于2020-11-08）. 参数|newspaper=与模板{{cite web}}不匹配（建议改用{{cite news}}或|website=） (帮助)

wsj.com

Grant, Charley. Surprise Drug Approval Is Holiday Gift for Biogen. Wall Street Journal. 2016-12-27 [2016-12-27]. ISSN 0099-9660. （原始内容存档于2020-11-08）. 参数|newspaper=与模板{{cite web}}不匹配（建议改用{{cite news}}或|website=） (帮助)

zjol.com.cn

zj.zjol.com.cn

https://zj.zjol.com.cn/news.html?id=1500220 （页面存档备份，存于互联网档案馆）引发争议的70万元“天价药”，怎样定价才算合理？